Thoracic mesenchymal malignant tumors and programed cell death ligand‐1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas

Abstract Background The current study aimed to evaluate the significance of clinicopathological factors, particularly the immunohistochemistry of programed cell death ligand‐1 (PD‐L1), in eight cases each of pulmonary sarcomatoid carcinoma (PSC) and malignant pleural mesothelioma (MPM) at our hospit...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kanji Otsubo, Hiroki Sakai, Hiroyuki Kimura, Tomoyuki Miyazawa, Hideki Marushima, Koji Kojima, Naoki Furuya, Masamichi Mineshita, Motohiro Chosokabe, Junki Koike, Hisashi Saji
Format:	article
Language:	EN
Published:	Wiley 2021
Subjects:	immune checkpoint inhibitor malignant pulmonary methotelioma programed cell death ligand‐1 pulmonary sarcomatoid carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Online Access:	https://doaj.org/article/7c341e2b3c4344559912d9d7076e951e
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Thoracic mesenchymal malignant tumors and programed cell death ligand‐1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas

Similar Items